Achaogen Inc., of South San Francisco, accelerated the expected timeline to report results from its ongoing phase III EPIC (Evaluating plazomicin in cUTI) registration trial of plazomicin, its lead candidate to treat serious bacterial infections due to multidrug-resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).